EMERGENT BIOSOLUTIONS INC (EBS)
US29089Q1058 - Common Stock
Commit To Purchase Emergent BioSolutions At $2, Earn 37.8% Annualized Using Options
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with...
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA)...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!
Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2023.
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023
EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Emergent BioSolutions (NYSE:EBS) just reported results for the fourth quarter o...
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion,...
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024,...
Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?
Investors in Emergent Biosolutions and EBS stock certainly have a big catalyst to cheer today, as the company announced a new CEO.
Notable Wednesday Option Activity: RPD, EBS, MPW
Emergent BioSolutions appoints Joseph C. Papa as CEO (NYSE:EBS)
Joseph C. Papa has been appointed as the new president and CEO of Emergent BioSolutions, replacing Haywood Miller, effective February 21, 2024.
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md.,...
Contrarian Calls: 7 Analyst ‘Sell’ Ratings That Should Be ‘Buys’
While it’s usually a good idea to trust Wall Street’s top experts, sometimes, it’s worthwhile to consider contrarian analyst picks.
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health...
Commit To Buy Emergent BioSolutions At $2.50, Earn 64% Annualized Using Options
Why Is Icosavax (ICVX) Stock Up 46% Today?
Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share.
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023
EBS stock results show that Emergent BioSolutions missed analyst estimates for earnings per share but beat on revenue for the third quarter of 2023.
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Beats Revenue for Q3 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Emergent BioSolutions (NYSE:EBS) just reported results for the third quarter of...